Literature DB >> 1985160

When to randomize?

S Durrleman1, R Simon.   

Abstract

Many clinical trials address the question of the duration of therapy or whether initial therapy can be improved by the addition of a consolidation or maintenance regimen. For such clinical trials, the question of when to perform the randomization is often difficult. Conventional statistical wisdom prescribes that randomization should take place as late as possible before treatment is effected. This is not always possible or desirable, however. In this report, we describe the factors that are influenced by the timing of randomization, quantify how timing affects these factors, and attempt to provide a tool to help investigators and statisticians determine the appropriate time to randomize for individual studies and particular circumstances.

Mesh:

Year:  1991        PMID: 1985160     DOI: 10.1200/JCO.1991.9.1.116

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  5 in total

1.  Design Issues in Randomized Clinical Trials of Maintenance Therapies.

Authors:  Boris Freidlin; Richard F Little; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2015-08-18       Impact factor: 13.506

2.  Always randomize as late as possible.

Authors:  Erik van Werkhoven; Parvin Tajik; Patrick M Bossuyt
Journal:  Gastric Cancer       Date:  2019-04-08       Impact factor: 7.370

3.  Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect.

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Clin Oncol       Date:  2018-06-27       Impact factor: 44.544

4.  Introducing the student and trainee to biomedical experimentation--a selective annotated bibliography.

Authors:  W E Ottowitz; U Halbreich
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

5.  Participation in clinical trials: is it state-of-the-art treatment for African Americans and other people of color?

Authors:  C R Thomas; H A Pinto; M Roach; C B Vaughn
Journal:  J Natl Med Assoc       Date:  1994-03       Impact factor: 1.798

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.